The Path From NIH Funding of Basic Science to New Therapeutics @UCSFDepartmentofMedicine
The Path From NIH Funding of Basic Science to New Therapeutics  @UCSFDepartmentofMedicine
Uploaded April 2025 | Updated November 2026, 3 hours ago
How does bench science get to the bedside? Now, more than ever, understanding how NIH-funded basic science research leads to groundbreaking medical treatments is crucial.

Richard Lifton, an internationally renowned genetics researcher and president of Rockefeller University, will discuss the translation of fundamental discoveries into therapeutic innovations, bridging the gap between laboratory research and clinical applications. Attendees will gain insights into the funding process, the challenges of therapeutic development, and the impact of scientific advancements on public health.

Speaker:
Richard Lifton, MD, PhD, is the president of The Rockefeller University, the former chair of Genetics at Yale University, and the founder of the Yale Center for Genome Analysis. He serves as a director at Roche and its subsidiary, Genentech. Lifton has also served on the Advisory Council to the NIH Director, co-chaired the National Academy of Sciences and Royal Society's International Commission on the Clinical Use of Germline Genome Editing, and co-chaired the White House and NIH's Precision Medicine Planning Group. He was awarded the Breakthrough Prize in Life Sciences and the Association of American Physicians' Kober Medal.

Program
Bob Wachter: Introduction
2:15-54:15 — Richard Lifton, MD, PhD
54:15-59:28 — Q&A

See previous Medical Grand Rounds:

March 25: More Money, Fewer Problems? Examining Guaranteed Income and Housing Stability
• youtu.be/pwwG1y4_gU8
March 11: Air Pollution, Asthma, Allergy, and the Exposome
• youtu.be/RK3T0UAGE0k
February 25: Updates in Large Vessel Vasculitis
• youtu.be/gQX8Ewjr-kI
February 18: The 27th Annual Reza Gandjei Lecture: Focusing on Health Care Equity
• youtu.be/7Z7FM-Apd2s
The Path From NIH Funding of Basic Science to New TherapeuticsRebuilding What Weve Lost in Covid: A Perspective from the ICUFrom Pipettes to Populations: Building an Integrated Program for ID Research and EducationThe Hypertension Control Paradox: Why America Is Stuck (And What We Can Do About It)How Hospital Norms and Organizational Factors Shape End-of-Life CareARDS: New Global Definition, Current Therapies, and Implementing Precision Critical CareCovid-19: Vaccines, Boosters, and Outpatient TherapiesHollander Rounds: A Clinical Problem-Solving CaseExploring Barriers to Giving and Receiving Feedback in the DOM31st Annual Alice Hamilton Lecture: Dust in the Lungs, an Ancient Disease Still with UsAddressing the Crisis of Clinician Burnout — A Conversation with Tait ShanafeltOmicron in Mid-December: What Have We Learned and What Does it Mean?
UCSF Department of Medicine |

The Path From NIH Funding of Basic Science to New Therapeutics

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER